Financhill
Sell
12

ZTS Quote, Financials, Valuation and Earnings

Last price:
$163.10
Seasonality move :
5.79%
Day range:
$162.25 - $164.14
52-week range:
$144.80 - $200.33
Dividend yield:
1.11%
P/E ratio:
29.48x
P/S ratio:
7.92x
P/B ratio:
15.14x
Volume:
2.8M
Avg. volume:
3.5M
1-year change:
-5.32%
Market cap:
$72.2B
Revenue:
$9.3B
EPS (TTM):
$5.47

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
ZTS
Zoetis
$2.3B $1.36 0.79% 6.7% $202.58
ALNY
Alnylam Pharmaceuticals
$580.6M -$0.14 20.07% -15.81% $304.87
LLY
Eli Lilly and
$13.4B $5.07 45.75% 89.16% $1,010.47
MRK
Merck &
$15.5B $1.67 -1.15% 13.5% $112.29
PFE
Pfizer
$17.3B $0.46 -3.03% 29.69% $31.32
WST
West Pharmaceutical Services
$740.9M $1.73 -1.45% -21.05% $286.12
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
ZTS
Zoetis
$161.26 $202.58 $72.2B 29.48x $0.50 1.11% 7.92x
ALNY
Alnylam Pharmaceuticals
$253.55 $304.87 $32.8B -- $0.00 0% 14.40x
LLY
Eli Lilly and
$837.01 $1,010.47 $751.8B 71.48x $1.50 0.65% 16.80x
MRK
Merck &
$94.02 $112.29 $237.5B 13.97x $0.81 3.36% 3.72x
PFE
Pfizer
$26.21 $31.32 $148.5B 18.59x $0.43 6.45% 2.35x
WST
West Pharmaceutical Services
$230.11 $286.12 $16.6B 34.40x $0.21 0.36% 5.86x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
ZTS
Zoetis
57.94% 0.877 9.3% 0.97x
ALNY
Alnylam Pharmaceuticals
93.86% 2.332 3.37% 2.61x
LLY
Eli Lilly and
70.33% 0.371 5.05% 0.59x
MRK
Merck &
44.49% 0.543 15.58% 0.84x
PFE
Pfizer
41.92% 0.618 43.87% 0.82x
WST
West Pharmaceutical Services
7.02% 1.553 0.92% 1.88x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
ZTS
Zoetis
$1.6B $765M 21.48% 49.71% 33.79% $689M
ALNY
Alnylam Pharmaceuticals
$490.3M -$105.2M -29.16% -- -26.13% -$103.8M
LLY
Eli Lilly and
$11.1B $5.8B 25.09% 80.24% 38.89% $726.6M
MRK
Merck &
$11.8B $4.3B 21.67% 40.25% 28.79% $2.5B
PFE
Pfizer
$11.9B $3.2B 5.09% 8.91% 4.1% $5.8B
WST
West Pharmaceutical Services
$273.6M $169.8M 16.88% 18.15% 21.92% $85.2M

Zoetis vs. Competitors

  • Which has Higher Returns ZTS or ALNY?

    Alnylam Pharmaceuticals has a net margin of 25.08% compared to Zoetis's net margin of -14.12%. Zoetis's return on equity of 49.71% beat Alnylam Pharmaceuticals's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ZTS
    Zoetis
    69.49% $1.29 $11.3B
    ALNY
    Alnylam Pharmaceuticals
    82.67% -$0.65 $1.1B
  • What do Analysts Say About ZTS or ALNY?

    Zoetis has a consensus price target of $202.58, signalling upside risk potential of 25.62%. On the other hand Alnylam Pharmaceuticals has an analysts' consensus of $304.87 which suggests that it could grow by 20.24%. Given that Zoetis has higher upside potential than Alnylam Pharmaceuticals, analysts believe Zoetis is more attractive than Alnylam Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    ZTS
    Zoetis
    10 5 0
    ALNY
    Alnylam Pharmaceuticals
    11 9 1
  • Is ZTS or ALNY More Risky?

    Zoetis has a beta of 0.941, which suggesting that the stock is 5.862% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals has a beta of 0.392, suggesting its less volatile than the S&P 500 by 60.76%.

  • Which is a Better Dividend Stock ZTS or ALNY?

    Zoetis has a quarterly dividend of $0.50 per share corresponding to a yield of 1.11%. Alnylam Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zoetis pays 31.62% of its earnings as a dividend. Alnylam Pharmaceuticals pays out -- of its earnings as a dividend. Zoetis's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios ZTS or ALNY?

    Zoetis quarterly revenues are $2.3B, which are larger than Alnylam Pharmaceuticals quarterly revenues of $593.2M. Zoetis's net income of $581M is higher than Alnylam Pharmaceuticals's net income of -$83.8M. Notably, Zoetis's price-to-earnings ratio is 29.48x while Alnylam Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zoetis is 7.92x versus 14.40x for Alnylam Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ZTS
    Zoetis
    7.92x 29.48x $2.3B $581M
    ALNY
    Alnylam Pharmaceuticals
    14.40x -- $593.2M -$83.8M
  • Which has Higher Returns ZTS or LLY?

    Eli Lilly and has a net margin of 25.08% compared to Zoetis's net margin of 32.59%. Zoetis's return on equity of 49.71% beat Eli Lilly and's return on equity of 80.24%.

    Company Gross Margin Earnings Per Share Invested Capital
    ZTS
    Zoetis
    69.49% $1.29 $11.3B
    LLY
    Eli Lilly and
    82.24% $4.88 $47.9B
  • What do Analysts Say About ZTS or LLY?

    Zoetis has a consensus price target of $202.58, signalling upside risk potential of 25.62%. On the other hand Eli Lilly and has an analysts' consensus of $1,010.47 which suggests that it could grow by 20.72%. Given that Zoetis has higher upside potential than Eli Lilly and, analysts believe Zoetis is more attractive than Eli Lilly and.

    Company Buy Ratings Hold Ratings Sell Ratings
    ZTS
    Zoetis
    10 5 0
    LLY
    Eli Lilly and
    16 4 0
  • Is ZTS or LLY More Risky?

    Zoetis has a beta of 0.941, which suggesting that the stock is 5.862% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.817%.

  • Which is a Better Dividend Stock ZTS or LLY?

    Zoetis has a quarterly dividend of $0.50 per share corresponding to a yield of 1.11%. Eli Lilly and offers a yield of 0.65% to investors and pays a quarterly dividend of $1.50 per share. Zoetis pays 31.62% of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios ZTS or LLY?

    Zoetis quarterly revenues are $2.3B, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Zoetis's net income of $581M is lower than Eli Lilly and's net income of $4.4B. Notably, Zoetis's price-to-earnings ratio is 29.48x while Eli Lilly and's PE ratio is 71.48x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zoetis is 7.92x versus 16.80x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ZTS
    Zoetis
    7.92x 29.48x $2.3B $581M
    LLY
    Eli Lilly and
    16.80x 71.48x $13.5B $4.4B
  • Which has Higher Returns ZTS or MRK?

    Merck & has a net margin of 25.08% compared to Zoetis's net margin of 23.96%. Zoetis's return on equity of 49.71% beat Merck &'s return on equity of 40.25%.

    Company Gross Margin Earnings Per Share Invested Capital
    ZTS
    Zoetis
    69.49% $1.29 $11.3B
    MRK
    Merck &
    75.5% $1.48 $83.5B
  • What do Analysts Say About ZTS or MRK?

    Zoetis has a consensus price target of $202.58, signalling upside risk potential of 25.62%. On the other hand Merck & has an analysts' consensus of $112.29 which suggests that it could grow by 19.43%. Given that Zoetis has higher upside potential than Merck &, analysts believe Zoetis is more attractive than Merck &.

    Company Buy Ratings Hold Ratings Sell Ratings
    ZTS
    Zoetis
    10 5 0
    MRK
    Merck &
    11 10 0
  • Is ZTS or MRK More Risky?

    Zoetis has a beta of 0.941, which suggesting that the stock is 5.862% less volatile than S&P 500. In comparison Merck & has a beta of 0.348, suggesting its less volatile than the S&P 500 by 65.24%.

  • Which is a Better Dividend Stock ZTS or MRK?

    Zoetis has a quarterly dividend of $0.50 per share corresponding to a yield of 1.11%. Merck & offers a yield of 3.36% to investors and pays a quarterly dividend of $0.81 per share. Zoetis pays 31.62% of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios ZTS or MRK?

    Zoetis quarterly revenues are $2.3B, which are smaller than Merck & quarterly revenues of $15.6B. Zoetis's net income of $581M is lower than Merck &'s net income of $3.7B. Notably, Zoetis's price-to-earnings ratio is 29.48x while Merck &'s PE ratio is 13.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zoetis is 7.92x versus 3.72x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ZTS
    Zoetis
    7.92x 29.48x $2.3B $581M
    MRK
    Merck &
    3.72x 13.97x $15.6B $3.7B
  • Which has Higher Returns ZTS or PFE?

    Pfizer has a net margin of 25.08% compared to Zoetis's net margin of 2.31%. Zoetis's return on equity of 49.71% beat Pfizer's return on equity of 8.91%.

    Company Gross Margin Earnings Per Share Invested Capital
    ZTS
    Zoetis
    69.49% $1.29 $11.3B
    PFE
    Pfizer
    66.74% $0.07 $152.1B
  • What do Analysts Say About ZTS or PFE?

    Zoetis has a consensus price target of $202.58, signalling upside risk potential of 25.62%. On the other hand Pfizer has an analysts' consensus of $31.32 which suggests that it could grow by 19.48%. Given that Zoetis has higher upside potential than Pfizer, analysts believe Zoetis is more attractive than Pfizer.

    Company Buy Ratings Hold Ratings Sell Ratings
    ZTS
    Zoetis
    10 5 0
    PFE
    Pfizer
    6 13 1
  • Is ZTS or PFE More Risky?

    Zoetis has a beta of 0.941, which suggesting that the stock is 5.862% less volatile than S&P 500. In comparison Pfizer has a beta of 0.613, suggesting its less volatile than the S&P 500 by 38.72%.

  • Which is a Better Dividend Stock ZTS or PFE?

    Zoetis has a quarterly dividend of $0.50 per share corresponding to a yield of 1.11%. Pfizer offers a yield of 6.45% to investors and pays a quarterly dividend of $0.43 per share. Zoetis pays 31.62% of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend. Zoetis's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Pfizer's is not.

  • Which has Better Financial Ratios ZTS or PFE?

    Zoetis quarterly revenues are $2.3B, which are smaller than Pfizer quarterly revenues of $17.8B. Zoetis's net income of $581M is higher than Pfizer's net income of $410M. Notably, Zoetis's price-to-earnings ratio is 29.48x while Pfizer's PE ratio is 18.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zoetis is 7.92x versus 2.35x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ZTS
    Zoetis
    7.92x 29.48x $2.3B $581M
    PFE
    Pfizer
    2.35x 18.59x $17.8B $410M
  • Which has Higher Returns ZTS or WST?

    West Pharmaceutical Services has a net margin of 25.08% compared to Zoetis's net margin of 17.38%. Zoetis's return on equity of 49.71% beat West Pharmaceutical Services's return on equity of 18.15%.

    Company Gross Margin Earnings Per Share Invested Capital
    ZTS
    Zoetis
    69.49% $1.29 $11.3B
    WST
    West Pharmaceutical Services
    36.54% $1.78 $2.9B
  • What do Analysts Say About ZTS or WST?

    Zoetis has a consensus price target of $202.58, signalling upside risk potential of 25.62%. On the other hand West Pharmaceutical Services has an analysts' consensus of $286.12 which suggests that it could grow by 24.34%. Given that Zoetis has higher upside potential than West Pharmaceutical Services, analysts believe Zoetis is more attractive than West Pharmaceutical Services.

    Company Buy Ratings Hold Ratings Sell Ratings
    ZTS
    Zoetis
    10 5 0
    WST
    West Pharmaceutical Services
    7 2 0
  • Is ZTS or WST More Risky?

    Zoetis has a beta of 0.941, which suggesting that the stock is 5.862% less volatile than S&P 500. In comparison West Pharmaceutical Services has a beta of 1.088, suggesting its more volatile than the S&P 500 by 8.847%.

  • Which is a Better Dividend Stock ZTS or WST?

    Zoetis has a quarterly dividend of $0.50 per share corresponding to a yield of 1.11%. West Pharmaceutical Services offers a yield of 0.36% to investors and pays a quarterly dividend of $0.21 per share. Zoetis pays 31.62% of its earnings as a dividend. West Pharmaceutical Services pays out 12% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios ZTS or WST?

    Zoetis quarterly revenues are $2.3B, which are larger than West Pharmaceutical Services quarterly revenues of $748.8M. Zoetis's net income of $581M is higher than West Pharmaceutical Services's net income of $130.1M. Notably, Zoetis's price-to-earnings ratio is 29.48x while West Pharmaceutical Services's PE ratio is 34.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zoetis is 7.92x versus 5.86x for West Pharmaceutical Services. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ZTS
    Zoetis
    7.92x 29.48x $2.3B $581M
    WST
    West Pharmaceutical Services
    5.86x 34.40x $748.8M $130.1M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Roblox Stock a Buy, Sell or Hold?
Is Roblox Stock a Buy, Sell or Hold?

Gaming company Roblox (NYSE:RBLX) operates a massive platform that allows…

Is Shopify a Millionaire Maker?
Is Shopify a Millionaire Maker?

Shopify (NYSE:SHOP) is an eCommerce platform, business services provider and…

Is Alphabet Stock No Longer a Good Bet?
Is Alphabet Stock No Longer a Good Bet?

Alphabet tripled its price per share over the past 5…

Stock Ideas

Buy
52
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Sell
50
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Buy
54
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 40x

Alerts

Buy
82
EXOD alert for Mar 21

Exodus Movement [EXOD] is up 17.89% over the past day.

Buy
69
SIG alert for Mar 20

Signet Jewelers [SIG] is down 0.64% over the past day.

Sell
36
HQY alert for Mar 20

HealthEquity [HQY] is up 0.28% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock